Trial Profile

A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 30 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zastumotide (Primary) ; AS15
Indications Malignant melanoma
Focus Registrational; Therapeutic Use
Acronyms DERMA; MAGE3-AS15-MEL-005
Sponsors GlaxoSmithKline; GSK

Most Recent Events

12 May 2019 Trial has been discontinued in UK.
02 May 2019 This trial was completed in France, according to European Clinical Trials Database.
13 Jun 2018 Primary endpoint [Disease-free survival (In the gene signature-positive sub-population)] has not been met, as per the results published in the Lancet Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com